Harvard Apparatus Regenerative Technology, INC

Harvard Apparatus Regenerative Technology, Inc. has entered into two bridge loan agreements with its CEO, Junli He, totaling $400,000, to provide working capital.

Harvard Apparatus Regenerative Technology, Inc. has amended its Form 8-K to correctly report a $300,000 bridge loan from CEO Junli He, due April 13, 2027, or upon a $5 million capital raise.

Harvard Apparatus Regenerative Technology announced the first patient has been treated with its Cellspan Esophageal Implant (CEI) in a Phase 1 clinical trial at the Mayo Clinic.

Harvard Apparatus Regenerative Technology, Inc. has entered into a $300,000 bridge loan agreement with its Chairman and CEO, Junli He, to provide immediate working capital.

Harvard Apparatus Regenerative Technology, Inc. announced a $0.7 million private placement of common stock and significant corporate governance enhancements, including board expansion and proposed charter amendments.

Harvard Apparatus Regenerative Technology, Inc. has entered into a private placement agreement to sell 1.25 million shares of common stock for approximately $2.0 million, alongside significant corporate governance enhancements including board expansion and shareholder rights reforms.

Harvard Apparatus Regenerative Technology reports significant revenue growth in its Consumer Health segment while facing ongoing challenges in its regenerative biotech operations, underscoring its need for continued financing.

Harvard Apparatus Regenerative Technology reported increased product revenue and a reduced net loss for Q3 and the first nine months of 2025, but faces substantial doubt about its ability to continue as a going concern without further financing.

Harvard Apparatus Regenerative Technology reported a narrower net loss in Q2 2025, driven by consumer health product sales, but faces substantial doubt about its ability to continue as a going concern without further capital.

Harvard Apparatus Regenerative Technology reports a net loss for Q1 2025 and expresses substantial doubt about its ability to continue as a going concern without additional funding.

Harvard Apparatus Regenerative Technology reported its third quarter 2024 results, highlighting progress in clinical trials and growth in its consumer health products segment, while also noting ongoing financial challenges.

Harvard Apparatus Regenerative Technology reported its second quarter 2024 results, highlighting a decrease in operating expenses but also raising concerns about its ability to continue as a going concern due to substantial operating losses.

Harvard Apparatus Regenerative Technology, Inc. reports a significant accumulated deficit and auditor's going concern qualification, alongside delays in patient recruitment for its pivotal esophageal regeneration clinical trial, despite revenue growth in its consumer health segment.

Harvard Apparatus Regenerative Technology reports a going concern qualification due to recurring losses and the need for additional funding, while facing delays in patient recruitment for its esophageal regeneration clinical trial.

Harvard Apparatus Regenerative Technology, a clinical-stage biotech company, reported its full year 2023 results, highlighting progress in its esophageal regeneration clinical trial and the launch of longevity products.

Harvard Apparatus Regenerative Technology's CEO, He Junli, increased their stake by purchasing 3,000 shares of common stock.

Harvard Apparatus Regenerative Technology CEO, He Junli, purchased 300 shares of common stock at $1.98 per share.

Harvard Apparatus Regenerative Technology CEO He Junli acquired 11,225 shares of common stock at a weighted average price of $1.85.

Harvard Apparatus Regenerative Technology CEO, He Junli, purchased 4,050 shares of common stock at a weighted average price of $1.72, increasing beneficial ownership to 266,050 shares.

Harvard Apparatus Regenerative Technology, Inc. director Zhang Mao was granted 33,817 stock options with a $1.6 exercise price, comprising an annual equity grant and options in lieu of cash compensation, vesting over various future dates.

James E. Shmerling, a non-employee director of Harvard Apparatus Regenerative Technology, Inc., was granted 33,817 stock options with an exercise price of $1.60 per share as part of his compensation.

Harvard Apparatus Regenerative Technology, Inc. is holding its 2026 Annual Meeting of Stockholders on June 18, 2026, to elect directors, ratify auditors, and vote on executive compensation.

Harvard Apparatus Regenerative Technology (HRGN) is seeking stockholder approval for several key corporate governance changes, including a reverse stock split, board declassification, and amendments to allow special stockholder meetings.

Harvard Apparatus Regenerative Technology, Inc. will hold its annual meeting of stockholders on June 20, 2024, to vote on director elections, auditor ratification, executive compensation, and other business.